Asciminib Maintains Clear Edge Over Bosutinib in CML After 4 Years

Chronic myeloid leukemia (CML) has been transformed from a fatal disease into a manageable chronic condition through tyrosine kinase inhibitor (TKI) therapy. However, 13–31% of patients fail first-line treatment, and up to 60% experience second-line failure, creating a substantial population needing later-line options. Sequential TKI use increases mutation rates, resistance, and toxicity burden—problems compounded by the long lifespans now expected in CML patients, making tolerability as critical as efficacy.

ASCEMBL (NCT03106779) is an open-label, randomized phase 3 trial comparing asciminib 40 mg twice daily with bosutinib 500 mg once daily in patients with CML in chronic phase (CML-CP) who had received two or more prior TKIs. Patients were randomized 2:1 (asciminib n=157, bosutinib n=76) and stratified by baseline major cytogenetic response (MCyR) status. This report presents the end-of-study treatment analysis at a median follow-up of 3.7 years (cutoff: March 2023), the longest follow-up yet reported from this trial.

The primary efficacy endpoint—major molecular response (MMR, BCR::ABL1IS ≤0.1%)—remained robustly superior for asciminib at week 156: 33.8% versus 10.5% for bosutinib, with an adjusted risk difference of 23.2% (95% CI: 13.14–33.18; P<0.001). This gap was consistent with earlier timepoints: at week 24, MMR rates were 25.5% vs 13.2%, and at week 96, 37.6% vs 15.8%, demonstrating that asciminib responses deepened and were durable over time. Importantly, 49.0% of asciminib patients completed study treatment per protocol versus only 10.5% of bosutinib patients, reflecting both better tolerability and efficacy retention.

Safety results remained favorable for asciminib. Grade ≥3 adverse events occurred in 59.6% of asciminib patients versus 68.4% of bosutinib patients. Critically, AE-related treatment discontinuations were dramatically lower with asciminib (8.3% vs 27.6%), a difference that is clinically meaningful given the chronic nature of CML therapy. Lack of efficacy remained the most common discontinuation reason in both arms (asciminib 25.5%, bosutinib 36.8%). The median exposure duration was 156.0 weeks with asciminib versus only 30.5 weeks with bosutinib, further underscoring the tolerability advantage. For the first time, this analysis also reports outcomes for the 25 bosutinib patients who switched to asciminib due to lack of efficacy; only 2 achieved MMR by EOS, suggesting that earlier use of asciminib—before additional TKI exposure—may yield better outcomes.

These results solidify asciminib as the standard of care in late-line CML-CP. Its STAMP (Specifically Targeting the ABL Myristoyl Pocket) mechanism of action is distinct from ATP-competitive TKIs, enabling activity against many resistance mutations and offering a differentiated safety profile. The longevity implications are significant: as CML patients live longer, minimizing cumulative toxicity—including arterial occlusive events, pleural effusions, and other class effects of older TKIs—becomes a priority for maintaining quality of life and treatment adherence over decades.